5.
Houg D, Bijlsma M
. The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma. Mol Cancer. 2018; 17(1):95.
PMC: 6003100.
DOI: 10.1186/s12943-018-0842-9.
View
6.
Lee J, Stone M, Porrett P, Thomas S, Komar C, Li J
. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature. 2019; 567(7747):249-252.
PMC: 6430113.
DOI: 10.1038/s41586-019-1004-y.
View
7.
Yu J, Green M, Li S, Sun Y, Journey S, Choi J
. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021; 27(1):152-164.
PMC: 8095049.
DOI: 10.1038/s41591-020-1131-x.
View
8.
Bailey P, Chang D, Nones K, Johns A, Patch A, Gingras M
. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016; 531(7592):47-52.
DOI: 10.1038/nature16965.
View
9.
Chan-Seng-Yue M, Kim J, Wilson G, Ng K, Figueroa E, OKane G
. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020; 52(2):231-240.
DOI: 10.1038/s41588-019-0566-9.
View
10.
Collisson E, Sadanandam A, Olson P, Gibb W, Truitt M, Gu S
. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011; 17(4):500-3.
PMC: 3755490.
DOI: 10.1038/nm.2344.
View
11.
Rashid N, Peng X, Jin C, Moffitt R, Volmar K, Belt B
. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. Clin Cancer Res. 2019; 26(1):82-92.
PMC: 6942634.
DOI: 10.1158/1078-0432.CCR-19-1467.
View
12.
Moffitt R, Marayati R, Flate E, Volmar K, Loeza S, Hoadley K
. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015; 47(10):1168-78.
PMC: 4912058.
DOI: 10.1038/ng.3398.
View
13.
Puleo F, Nicolle R, Blum Y, Cros J, Marisa L, Demetter P
. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. Gastroenterology. 2018; 155(6):1999-2013.e3.
DOI: 10.1053/j.gastro.2018.08.033.
View
14.
Halbrook C, Lyssiotis C, Pasca di Magliano M, Maitra A
. Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729-1754.
PMC: 10182830.
DOI: 10.1016/j.cell.2023.02.014.
View
15.
Dreyer S, Upstill-Goddard R, Paulus-Hock V, Paris C, Lampraki E, Dray E
. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology. 2020; 160(1):362-377.e13.
PMC: 8167930.
DOI: 10.1053/j.gastro.2020.09.043.
View
16.
Labrie M, Brugge J, Mills G, Zervantonakis I
. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer. 2022; 22(6):323-339.
PMC: 9149051.
DOI: 10.1038/s41568-022-00454-5.
View
17.
Morrison A, Byrne K, Vonderheide R
. Immunotherapy and Prevention of Pancreatic Cancer. Trends Cancer. 2018; 4(6):418-428.
PMC: 6028935.
DOI: 10.1016/j.trecan.2018.04.001.
View
18.
Zheng L, Ding D, Edil B, Judkins C, Durham J, Thomas 2nd D
. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. Clin Cancer Res. 2020; 27(5):1278-1286.
PMC: 7925374.
DOI: 10.1158/1078-0432.CCR-20-2974.
View
19.
Balachandran V, Luksza M, Zhao J, Makarov V, Moral J, Remark R
. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017; 551(7681):512-516.
PMC: 6145146.
DOI: 10.1038/nature24462.
View